Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis.
The effects of long-term interferon- beta-1b treatment on cognitive functioning in multiple sclerosis: a 16-year longitudinal study.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Determination and characterization of a cannabinoid receptor in rat brain.
Sex-related factors in multiple sclerosis susceptibility and progression.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Rescue Therapy Using Rituximab for Multiple Sclerosis.
The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service.
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis.
Effectiveness of glatiramer acetate compared to other multiple sclerosis therapies.
Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study.
Antiviral drug ganciclovir is a potent inhibitor of microglial proliferation and neuroinflammation.
Centocor briefing document for Ustekinumab, submitted to FDA
Volumetric comparisons of supratentorial white matter hyperintensities on FLAIR MRI in patients with migraine and multiple sclerosis.
Roche's MabThera approved for two vasculitis indications in UK
White matter astrocytes in health and disease.
Significant Percentage of MS Patients Receiving Alemtuzumab in Genzyme’s Phase 2 Trial Remain Free of Clinically Active Disease
Guillain-Barré syndrome: clinical profile and management.
Remyelination therapy goes to trial for multiple sclerosis
Urodynamic and physiologic patterns associated with the common causes of neurogenic bladder in adults.
Immunomodulatory effects of Vitamin D in multiple sclerosis.
Risk factors for rare diseases can be risky to define: PML and natalizumab.
Interferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trial.

Pages